Antibody drugs targeting SARS-CoV-2: Time for a rethink? - 16/06/24
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) heavily burdens human health. Multiple neutralizing antibodies (nAbs) have been issued for emergency use or tested for treating infected patients in the clinic. However, SARS-CoV-2 variants of concern (VOC) carrying mutations reduce the effectiveness of nAbs by preventing neutralization. Uncoding the mutation profile and immune evasion mechanism of SARS-CoV-2 can improve the outcome of Ab-mediated therapies. In this review, we first outline the development status of anti-SARS-CoV-2 Ab drugs and provide an overview of SARS-CoV-2 variants and their prevalence. We next focus on the failure causes of anti-SARS-CoV-2 Ab drugs and rethink the design strategy for developing new Ab drugs against COVID-19. This review provides updated information for the development of therapeutic Ab drugs against SARS-CoV-2 variants.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Strategies for designing innovative antibody drugs to combat the COVID-19 pandemic. Practical approaches include the use of antibody mixtures, the targeting of generic or nonhotspot mutational epitopes, and the use of antibody-modified nanomaterials. In addition, engineering new functional antibodies, seeking new targets and other methods may also be considered.
Strategies for designing innovative antibody drugs to combat the COVID-19 pandemic. Practical approaches include the use of antibody mixtures, the targeting of generic or nonhotspot mutational epitopes, and the use of antibody-modified nanomaterials. In addition, engineering new functional antibodies, seeking new targets and other methods may also be considered.Le texte complet de cet article est disponible en PDF.
Highlights |
• | Summarize the SARS-CoV-2 variants, overview the neutralizing antibody drugs. |
• | Clarify the failure causes of antibody drugs and mutation-caused immune evasion. |
• | Rethink the design strategies of antibody drugs for addressing mutation challenges. |
Keywords : SARS-CoV-2, Mutations, Therapeutic antibody, Immune evasion, Design strategy
Plan
Vol 176
Article 116900- juillet 2024 Retour au numéro
Article précédent
- Covalent conjugation and non-covalent complexation strategies for intracellular delivery of proteins using cell-penetrating peptides
- Yasaman Behzadipour, Shiva Hemmati
- The experimental significance of isorhamnetin as an effective therapeutic option for cancer: A comprehensive analysis
- Partha Biswas, Md. Abu Kaium, Md. Mohaimenul Islam Tareq, Sadia Jannat Tauhida, Md Ridoy Hossain, Labib Shahriar Siam, Anwar Parvez, Shabana Bibi, Md Hasibul Hasan, Md. Moshiur Rahman, Delwar Hosen, Md. Ariful Islam Siddiquee, Nasim Ahmed, Md. Sohel, Salauddin Al Azad, Albaraa H. Alhadrami, Mohamed Kamel, Mariam K. Alamoudi, Md. Nazmul Hasan, Mohamed M. Abdel-Daim
Bienvenue sur EM-consulte, la référence des professionnels de santé.